COAG
Hemab Therapeutics Holdings, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-37/100
Last price
28.37
▼ 2.22 (7.26%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
30.59
Day high
30.89
Day low
28.01
Volume
436.83K
Market cap
$1.33B
P/E (TTM)
—
52W range
23.00 – 55.42
Trailing performance
Returnvs SPY
1W
-12.98%
-14.9%
1M
-36.12%
-37.3%
3M
-16.29%
-20.8%
6M
—
-18.2%
YTD
-16.56%
-30.8%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on COAG open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
5.04M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 16, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 67.67K | $1.69M | Indirect |
| May 20, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.80K | $119.78K | Indirect |
| May 12, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 6.39K | $159.04K | Indirect |
| May 11, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 51.26K | $1.27M | Indirect |
| May 6, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.84M | $71.86M | Indirect |
| May 4, 26 | MARAGANORE JOHN M Director |
— | 35.95K | — | Direct |
| May 4, 26 | NOVO HOLDINGS A/S Beneficial Owner of more than 10% of a Class of Security |
— | 4.18M | — | Direct |
| May 4, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Director and Beneficial Owner of more than 10% of a Class of Security |
— | 4.84M | — | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
MARAGANORE JOHN M |
Director | 35.95K | Conversion of Exercise of derivative security |
NOVO HOLDINGS A/S |
Beneficial Owner of more than 10% of a Class of Security | 4.18M | Conversion of Exercise of derivative security |
RA CAPITAL HEALTHCARE FUND,L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$1.33B
Enterprise value$868.79M
Revenue (TTM)—
Gross profit—
EBITDA$-86.89M
Net income$-83.23M
EPS (TTM)$-4.33
Free cash flow—
Total cash$457.46M
Total debt$1.03M
Book value / share$9.73
Shares outstanding46.71M
Float20.31M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-11.18
PEG ratio—
Price / sales—
Price / book2.92
EV / revenue—
EV / EBITDA-10.00
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity0.23
Current ratio35.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $59.63M | $41.41M | +44.0% |
| Selling, general & admin | $10.49M | $8.97M | +16.9% |
| Total operating expense | $70.12M | $50.38M | +39.2% |
| Operating income | -$70.12M | -$50.38M | -39.2% |
| Net interest income | $1.97M | $3.74M | -47.2% |
| Pre-tax income | -$64.14M | -$48.52M | -32.2% |
| Tax provision | -$227.00K | $185.00K | -222.7% |
| Net income | -$63.91M | -$48.71M | -31.2% |
| Net income to common | -$63.91M | -$48.71M | -31.2% |
| Basic EPS | -2.33 | -1.77 | -31.3% |
| Diluted EPS | -2.33 | -1.77 | -31.3% |
| EBIT | -$70.12M | -$50.38M | -39.2% |
| EBITDA | -$69.81M | -$50.13M | -39.3% |
| Basic shares | 27.44M | 27.44M | 0.0% |
| Diluted shares | 27.44M | 27.44M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $87.97M | $74.41M | +18.2% |
| Cash & short-term investments | $185.49M | $88.33M | +110.0% |
| Total current assets | $192.55M | $93.23M | +106.5% |
| Property, plant & equipment | $1.70M | $2.57M | -33.7% |
| Total assets | $194.78M | $96.28M | +102.3% |
| Total current liabilities | $10.68M | $6.68M | +59.7% |
| Total debt | $1.22M | $1.73M | -29.3% |
| Total liabilities | $371.42M | $211.55M | +75.6% |
| Retained earnings | -$181.86M | -$117.94M | -54.2% |
| Shareholder equity | -$176.63M | -$115.27M | -53.2% |
| Working capital | $181.87M | $86.55M | +110.1% |
| Net tangible assets | -$176.63M | -$115.27M | -53.2% |
| Shares issued | 44.19M | 44.19M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$63.91M | -$48.71M | -31.2% |
| Depreciation & amortisation | $304.00K | $248.00K | +22.6% |
| Stock-based compensation | $2.01M | $1.91M | +5.5% |
| Change in working capital | $1.35M | $1.45M | -6.4% |
| Operating cash flow | -$61.48M | -$45.59M | -34.8% |
| Capital expenditure | -$16.00K | -$282.00K | +94.3% |
| Investing cash flow | -$81.48M | $61.90M | -231.6% |
| Financing cash flow | $156.30M | -$100.00K | +156,401.0% |
| Free cash flow | -$61.49M | -$45.87M | -34.0% |
| End cash position | $87.97M | $74.41M | +18.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $20.34M | $19.46M | $12.87M | $14.10M | +4.5% |
| Selling, general & admin | $5.74M | $4.15M | $3.18M | $2.46M | +38.4% |
| Total operating expense | $26.08M | $23.61M | $16.06M | $16.56M | +10.4% |
| Operating income | -$26.08M | -$23.61M | -$16.06M | -$16.56M | -10.4% |
| Net interest income | $2.86M | $1.22M | $335.00K | $473.00K | +134.5% |
| Pre-tax income | -$24.05M | -$22.68M | -$12.21M | -$15.50M | -6.1% |
| Tax provision | $97.00K | $12.00K | $4.00K | -$190.00K | +708.3% |
| Net income | -$24.15M | -$22.69M | -$12.21M | -$15.31M | -6.4% |
| Net income to common | -$24.15M | -$22.69M | -$12.21M | -$15.31M | -6.4% |
| Basic EPS | -0.80 | -0.51 | -0.44 | -0.56 | -55.8% |
| Diluted EPS | -0.80 | -0.51 | -0.44 | -0.56 | -55.8% |
| EBIT | -$26.08M | -$23.61M | -$16.06M | -$16.56M | -10.4% |
| EBITDA | -$26.00M | -$23.54M | -$15.98M | -$16.48M | -10.5% |
| Basic shares | 30.11M | 44.19M | 27.44M | 27.44M | -31.9% |
| Diluted shares | 30.11M | 44.19M | 27.44M | 27.44M | -31.9% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $237.37M | $49.86M | +376.1% |
| Cash & short-term investments | $457.46M | $163.53M | +179.7% |
| Total current assets | $464.00M | $169.43M | +173.9% |
| Property, plant & equipment | $1.50M | $1.59M | -5.7% |
| Total assets | $467.78M | $175.26M | +166.9% |
| Total current liabilities | $12.94M | $13.19M | -1.9% |
| Total debt | $1.03M | $1.06M | -3.5% |
| Total liabilities | $13.51M | $373.88M | -96.4% |
| Retained earnings | -$228.69M | -$204.54M | -11.8% |
| Shareholder equity | $454.27M | -$198.62M | +328.7% |
| Working capital | $451.05M | $156.24M | +188.7% |
| Net tangible assets | $454.27M | -$198.62M | +328.7% |
| Shares issued | 46.71M | 44.19M | +5.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$24.15M | -$22.69M | -$12.21M | -$15.31M | -6.4% |
| Depreciation & amortisation | $75.00K | $73.00K | $77.00K | $75.00K | +2.7% |
| Stock-based compensation | $2.02M | $1.32M | $494.00K | $459.00K | +52.9% |
| Change in working capital | $582.00K | $375.00K | -$2.42M | $1.43M | +55.2% |
| Operating cash flow | -$22.64M | -$21.58M | -$15.33M | -$13.03M | -4.9% |
| Capital expenditure | -$23.00K | -$112.00K | — | -$16.00K | +79.5% |
| Investing cash flow | -$107.44M | -$15.85M | $21.50M | -$5.99M | -578.0% |
| Financing cash flow | $317.58M | -$460.00K | -$30.00K | -$29.00K | +69,138.9% |
| Free cash flow | -$22.66M | -$21.70M | -$15.33M | -$13.05M | -4.4% |
| End cash position | $237.37M | $49.86M | $61.49M | $55.35M | +376.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.82 | -0.80 | +2.0% |
| Mar 2026 | — | -23.98 | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.51 | 4 | $0 | — |
| Next quarter | -0.57 | 4 | $0 | — |
| Current year | -3.10 | 4 | $0 | — |
| Next year | -2.54 | 4 | $0 | 0.0% |
Analyst targets & ownership
Mean target$61.20
High target$65.00
Low target$58.00
Implied upside115.72%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders10.78%
Held by institutions92.43%
Institutions holding78
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
32.49
-12.68% from price
SMA 20
36.44
-22.15% from price
SMA 50
43.72
-35.11% from price
SMA 100
38.22
-25.77% from price
SMA 200
—
—
EMA 12
33.24
-14.66% from price
EMA 26
37.19
-23.72% from price
EMA 50
39.31
-27.83% from price
RSI (14)
19.2
Oversold
MACD (12,26,9)
-3.95
Hist -0.62
ATR (14)
2.55
8.99% of price
Realised vol 30D
59.8%
Annualised
Bollinger upper
45.43
20, 2σ
Bollinger lower
27.45
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.23
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
59.8%
Annualised
Market vol 1Y
12.2%
SPY, annualised
Max drawdown 1Y
-48.4%
Peak to trough
Max drawdown 5Y
-48.4%
Peak to trough
ATR 14
2.55
8.99% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.64M
Prior 2.03M
Change vs prior
+29.9%
Shorts adding
% of float
—
—
% of shares out
5.65%
Against total outstanding
Days to cover
7.5
Crowded exit
Float
20.31M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 17, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| May 26, 26 | Wedbush | INITIATED | — | Outperform |
| May 26, 26 | Jefferies | INITIATED | — | Buy |
| May 26, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| May 26, 26 | Goldman Sachs | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-24
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-04
Offering Registrations
S-1MEF · 2026-04-30
Offering Registrations
S-1/A · 2026-04-28
Offering Registrations
S-1/A · 2026-04-27
Headlines
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
Simply Wall St. · 8d ago
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
GlobeNewswire · 13d ago
Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study
MT Newswires · 20d ago
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
GlobeNewswire · 20d ago
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating
MT Newswires · 57d ago
Hemab Therapeutics' Q2 Net Loss Narrows
MT Newswires · 57d ago
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 57d ago
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
GlobeNewswire · 85d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.